Science & Technology Review
|
2016, 34(11): 53-59
• Special Issues •
Technical composition and developments of patents regarding Liraglutide
Full
HUANG Jia1, WANG Jun2
Affiliations
1. Pharmacy and Biotech Examination Department, Patent Office, State Intellectual Property Office of the PRC, Beijing 100088, China;
2. Chemistry Examination Department, Patent Office, State Intellectual Property Office of the PRC, Beijing 100088, China
Published: 2016-06-13
doi: 10.3981/j.issn.1000-7857.2016.11.009
Outline
Liraglutide is a GLP-1 analogue produced from yeasts via the gene recombination, mainly used in treatment of type Ⅱ diabetes. The patents related with liraglutide have been increasing since 1999 with diverse technical solutions, which could be categorized into the core patents, the DDS patents, the combination patents and the second medicinal use patents. The core patents are to gain primary interests, the DDS patents create shortcuts to an alreadypatented medicine, the combination patents prevent possible infringements involving liraglutde, and the second medicinal use patents can lead to a re-capture of the market.
liraglutide
/
patent
/
technical composition
黄嘉, 王俊.
利拉鲁肽专利技术构成及发展.
科技导报,
2016
, 34
(11)
: 53
-59
.
DOI: 10.3981/j.issn.1000-7857.2016.11.009
HUANG Jia, WANG Jun.
Technical composition and developments of patents regarding Liraglutide[J].
Science & Technology Review,
2016
, 34
(11)
: 53
-59
.
DOI: 10.3981/j.issn.1000-7857.2016.11.009
Year 2016 volume 34 Issue 11
PDF
518
121
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2016.11.009
- Receive Date:2016-05-17
- Online Date:2016-06-29
- Published:2016-06-13